Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Upstream Bio, Inc.NASDAQ: UPB
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $598K, compared with -$34K a year earlier. Trailing-twelve-month financing cash flow was $3.07M. Over 3 fiscal years it compounded at -37.4% a year.
Context
- Financing cash flow amounted to 85.5% of revenue in FY2025, down 17590.0 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $598K or moves back toward the trailing-twelve-month quarterly average of $768.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 2.44M USD
- Year-over-year change
- -99.4%
- 3-year CAGR
- -37.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.44M | -99.4% |
| FY2024 | 2024-12-31 | 418.91M | +223.4% |
| FY2023 | 2023-12-31 | 129.55M | +1200.3% |
| FY2022 | 2022-12-31 | 9.96M | — |
Financing Cash Flow vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -99.2% is the lowest of 10, against a peer median of +56.8%.
- Financing cash flow amounts to 92.5% of revenue for UPB, versus a peer median of 465.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $759.69M USD | +242.5% | +93.5% | 839.5% | |
| LTM Mar 2026 | $648.66M USD | +56.8% | +53.6% | — | |
| LTM Sep 2026 | $554.65M USD | +115.5% | -15.9% | — | |
| LTM Mar 2026 | $489.54M USD | +101.0% | +93.7% | 681.8% | |
| LTM Jun 2026 | $463.47M USD | +110.3% | -82.3% | 4478.0% | |
| LTM Mar 2026 | $165.06M USD | +31.3% | -31.7% | 249.7% | |
| LTM Sep 2026 | €112.22M EUR | -30.3% | +164.8% | — | |
| LTM Mar 2026 | $72.47M USD | -70.7% | -56.0% | 12.2% | |
| LTM Mar 2026 | $20.66M USD | -94.1% | -57.0% | 9.5% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $3.07M USD | -99.2% | -37.4% | 92.5% |
| Peer median (excluding UPB) | — | +56.8% | -15.9% | 465.8% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Depreciation & Amortization | 7K | 60K | 89K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.28M | 3.43M | 6M | 10.33M |
| Change in Working Capital | 3.41M | (4.31M) | 1.87M | 589K |
| Accounts Receivables | (412K) | 314K | (515K) | (55K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 462K | 1.28M | 2.02M | (1.28M) |
| Other Working Capital | 3.36M | (5.9M) | 371K | 1.93M |
| Other Non-Cash Items | 149K | (16.57M) | (4.33M) | 561K |
| Operating Cash Flow | (19.02M) | (37.93M) | (59.17M) | (133.28M) |
| Capital Expenditures | (82K) | (144K) | (511K) | (165K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (128.99M) | (290.61M) | (385.88M) |
| Sales of Investments | 0 | 46.29M | 231.64M | 292.56M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (82K) | (82.84M) | (59.49M) | (93.48M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.96M | 129.55M | 272.72M | 2.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37K) | 118K | (3.74M) | 0 |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.14M) | 8.78M | 300.25M | (224.31M) |
| Free Cash Flow | (19.1M) | (38.07M) | (59.68M) | (133.28M) |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.